Reckitt Benckiser Group PLC (OTCMKTS:RBGLY) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Reckitt Benckiser Group PLC (OTCMKTS:RBGLY) have been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and two have given a strong buy recommendation to the company.

RBGLY has been the subject of several research reports. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Reckitt Benckiser Group in a research note on Tuesday, June 30th. Zacks Research upgraded Reckitt Benckiser Group from a “strong sell” rating to a “hold” rating in a research note on Friday, August 28th. Jefferies Financial Group raised shares of Reckitt Benckiser Group from a “hold” rating to a “buy” rating in a report on Tuesday, July 21st. Finally, BNP Paribas Exane lowered Reckitt Benckiser Group from an “outperform” rating to a “neutral” rating in a research note on Wednesday, September 2nd.

Reckitt Benckiser Group Price Performance

Shares of RBGLY opened at $13.66 on Friday. Reckitt Benckiser Group has a 52-week low of $12.02 and a 52-week high of $17.80. The business’s 50 day moving average price is $13.90 and its two-hundred day moving average price is $13.68. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.85 and a quick ratio of 0.63.

About Reckitt Benckiser Group

Reckitt Benckiser Group plc, operating under the Reckitt name, is a global consumer health and hygiene company headquartered in Slough, England. The company develops, manufactures and markets products intended to support personal health, household hygiene and nutrition, selling through retailers, pharmacies and e-commerce channels.

Its portfolio includes well-known brands such as Dettol and Lysol in hygiene; Durex in sexual wellness; Nurofen, Strepsils and Mucinex in consumer health; and Finish in dishwashing products.